FBLG
FibroBiologics, Inc.
Price Chart
Latest Quote
$0.78
+0.01 (+1.79%)
Current Price
| Previous Close | $0.77 |
| Open | $0.76 |
| Day High | $0.81 |
| Day Low | $0.75 |
| Volume | 148,573 |
Stock Information
| Shares Outstanding | 5.21M |
| Total Debt | $2.48M |
| Cash Equivalents | $1.48M |
| Net Income | $-18.68M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $4.08M |
| EPS (TTM) | $-7.02 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $5.01M |
| Income | $-18.68M |
| Book/sh | $0.74 |
| Cash/sh | $0.28 |
| Employees | 15 |
Financial Ratios
| Quick Ratio | 0.81 |
| Current Ratio | 1.59 |
| Debt/Eq | 95.31 |
Returns & Margins
| ROA | -123.72% |
| ROE | -754.75% |
Ownership
| Insider Ownership | 12.62% |
| Institutional Ownership | 12.51% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.17 |
| P/B | 1.06 |
Analyst Data
| Recommendation | none |
| Target Price | $13.50 |
Technical Indicators
| SMA20 | $0.99 |
| SMA50 | $1.18 |
| SMA200 | $5.46 |
| RSI | 14.41 |
| ATR | 0.0879 |
| Shares Float | 4.57M |
| Short Float | 2.77% |
| Short Ratio | 0.40 |
| Volatility | 1.15 |
| Rel Volume | 1.11 |
Performance History
| Week | -15.79% |
| Month | -25.33% |
| Quarter | -84.57% |
| 6 Months | -85.80% |
| YTD | -83.67% |
| Year | -94.54% |
| 10 Years | -99.87% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $0.78 | 148,573 |
| 2026-06-18 | $0.77 | 160,400 |
| 2026-06-17 | $0.80 | 135,800 |
| 2026-06-16 | $0.81 | 136,100 |
| 2026-06-15 | $0.89 | 216,200 |
| 2026-06-12 | $0.93 | 236,600 |
| 2026-06-11 | $0.96 | 53,200 |
| 2026-06-10 | $0.95 | 108,400 |
| 2026-06-09 | $0.93 | 136,800 |
| 2026-06-08 | $1.01 | 74,400 |
| 2026-06-05 | $1.03 | 74,900 |
| 2026-06-04 | $1.07 | 235,500 |
| 2026-06-03 | $1.07 | 297,900 |
| 2026-06-02 | $1.05 | 101,800 |
| 2026-06-01 | $1.12 | 91,200 |
| 2026-05-29 | $1.16 | 64,900 |
| 2026-05-28 | $1.13 | 172,000 |
| 2026-05-27 | $1.12 | 105,000 |
| 2026-05-26 | $1.06 | 60,600 |
| 2026-05-22 | $1.05 | 66,000 |
About FibroBiologics, Inc.
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $204,000 | $20,000 | $147,000 | $654,000 |
| Total Expenses | $16,649,000 | $13,737,000 | $8,889,000 | $4,467,000 |
| Other Income Expense | $-2,040,000 | $2,345,000 | $-7,449,000 | - |
| Other Non Operating Income Expenses | $-2,392,000 | $-3,377,000 | $-213,000 | - |
| Net Non Operating Interest Income Expense | $43,000 | $231,000 | $-147,000 | $-654,000 |
| Interest Expense Non Operating | $204,000 | $20,000 | $147,000 | $654,000 |
| Operating Expense | $16,649,000 | $13,737,000 | $8,889,000 | $4,467,000 |
| General And Administrative Expense | $9,242,000 | $9,233,000 | $6,521,000 | $3,320,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-18,646,000 | $-11,161,000 | $-16,485,000 | $-5,121,000 |
| Net Interest Income | $43,000 | $231,000 | $-147,000 | $-654,000 |
| Interest Income | $247,000 | $251,000 | $0 | - |
| Normalized Income | $-18,998,000 | $-16,883,000 | $-9,249,000 | $-5,121,000 |
| Net Income From Continuing And Discontinued Operation | $-18,646,000 | $-11,161,000 | $-16,485,000 | $-5,121,000 |
| Total Operating Income As Reported | $-16,649,000 | $-13,737,000 | $-8,889,000 | $-4,467,000 |
| Net Income Common Stockholders | $-18,646,000 | $-11,161,000 | $-19,058,000 | $-5,121,000 |
| Net Income | $-18,646,000 | $-11,161,000 | $-16,485,000 | $-5,121,000 |
| Net Income Including Noncontrolling Interests | $-18,646,000 | $-11,161,000 | $-16,485,000 | $-5,121,000 |
| Net Income Continuous Operations | $-18,646,000 | $-11,161,000 | $-16,485,000 | $-5,121,000 |
| Pretax Income | $-18,646,000 | $-11,161,000 | $-16,485,000 | $-5,121,000 |
| Interest Income Non Operating | $247,000 | $251,000 | $0 | - |
| Operating Income | $-16,649,000 | $-13,737,000 | $-8,889,000 | $-4,467,000 |
| Per Share | ||||
| Diluted EPS | $-8.40 | $-6.80 | $-11.74 | $-3.15 |
| Basic EPS | $-8.40 | $-6.80 | $-11.74 | $-3.15 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-17,962,000 | $-16,290,000 | $-8,665,000 | $-4,373,000 |
| Total Unusual Items | $352,000 | $5,722,000 | $-7,236,000 | - |
| Total Unusual Items Excluding Goodwill | $352,000 | $5,722,000 | $-7,236,000 | - |
| Reconciled Depreciation | $832,000 | $573,000 | $437,000 | $94,000 |
| EBITDA (Bullshit earnings) | $-17,610,000 | $-10,568,000 | $-15,901,000 | $-4,373,000 |
| EBIT | $-18,442,000 | $-11,141,000 | $-16,338,000 | $-4,467,000 |
| Diluted Average Shares | $2,233,025 | $1,643,753 | $1,624,603 | $1,623,860 |
| Basic Average Shares | $2,233,025 | $1,643,753 | $1,624,603 | $1,623,860 |
| Diluted NI Availto Com Stockholders | $-18,646,000 | $-11,161,000 | $-19,058,000 | $-5,121,000 |
| Gain On Sale Of Security | $352,000 | $5,722,000 | $-7,236,000 | - |
| Research And Development | $7,407,000 | $4,504,000 | $2,368,000 | $1,147,000 |
| Selling General And Administration | $9,242,000 | $9,233,000 | $6,521,000 | $3,320,000 |
| Other Gand A | $9,242,000 | $9,233,000 | $6,521,000 | $3,320,000 |
| Otherunder Preferred Stock Dividend | - | $0 | $2,573,000 | $0 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $6,156,000 | $2,735,000 | $1,253,000 | $-3,996,000 |
| Total Assets | $9,619,000 | $16,445,000 | $11,821,000 | $4,824,000 |
| Total Non Current Assets | $3,270,000 | $2,217,000 | $2,606,000 | $2,199,000 |
| Other Non Current Assets | $48,000 | - | - | - |
| Current Assets | $6,349,000 | $14,228,000 | $9,215,000 | $2,625,000 |
| Prepaid Assets | $1,455,000 | $225,000 | $36,000 | $29,000 |
| Cash Cash Equivalents And Short Term Investments | $4,894,000 | $13,985,000 | $9,163,000 | $2,266,000 |
| Cash And Cash Equivalents | $4,894,000 | $13,985,000 | $9,163,000 | $2,266,000 |
| Other Current Assets | - | $18,000 | $16,000 | $30,000 |
| Receivables | - | - | $0 | $300,000 |
| Loans Receivable | - | - | $0 | $300,000 |
| Debt | ||||
| Total Debt | $2,410,000 | $10,553,000 | $1,747,000 | $7,524,000 |
| Long Term Debt And Capital Lease Obligation | $1,704,000 | $984,000 | $1,385,000 | $1,747,000 |
| Current Debt And Capital Lease Obligation | $706,000 | $9,569,000 | $362,000 | $5,777,000 |
| Current Debt | - | $9,168,000 | - | $5,451,000 |
| Other Current Borrowings | - | $9,168,000 | - | $5,451,000 |
| Net Debt | - | - | - | $3,185,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,463,000 | $13,710,000 | $10,568,000 | $8,820,000 |
| Total Non Current Liabilities Net Minority Interest | $1,704,000 | $984,000 | $1,385,000 | $1,747,000 |
| Current Liabilities | $1,759,000 | $12,726,000 | $9,183,000 | $7,073,000 |
| Other Current Liabilities | $108,000 | $460,000 | $7,236,000 | $538,000 |
| Payables And Accrued Expenses | $945,000 | $2,697,000 | $1,585,000 | $758,000 |
| Payables | $945,000 | $2,697,000 | $1,585,000 | $758,000 |
| Accounts Payable | $945,000 | $2,697,000 | $1,444,000 | $758,000 |
| Other Non Current Liabilities | - | - | $1,000 | - |
| Other Payable | - | - | $141,000 | - |
| Equity | ||||
| Common Stock Equity | $6,156,000 | $2,735,000 | $1,253,000 | $-3,996,000 |
| Total Equity Gross Minority Interest | $6,156,000 | $2,735,000 | $1,253,000 | $-3,996,000 |
| Stockholders Equity | $6,156,000 | $2,735,000 | $1,253,000 | $-3,996,000 |
| Retained Earnings | $-54,164,000 | $-35,518,000 | $-24,357,000 | $-7,872,000 |
| Other Equity Interest | - | - | - | $1,461,000 |
| Other | ||||
| Ordinary Shares Number | $3,325,986 | $1,754,285 | $1,623,860 | $1,623,860 |
| Share Issued | $3,325,986 | $1,754,285 | $1,623,860 | $1,623,860 |
| Tangible Book Value | $6,156,000 | $2,735,000 | $1,253,000 | $-3,996,000 |
| Invested Capital | $6,156,000 | $11,903,000 | $1,253,000 | $1,455,000 |
| Working Capital | $4,590,000 | $1,502,000 | $32,000 | $-4,448,000 |
| Capital Lease Obligations | $2,410,000 | $1,385,000 | $1,747,000 | $2,073,000 |
| Total Capitalization | $6,156,000 | $2,735,000 | $1,253,000 | $-3,996,000 |
| Additional Paid In Capital | $60,319,000 | $38,253,000 | $25,609,000 | $2,414,000 |
| Capital Stock | $1,000 | $0 | $1,000 | $1,000 |
| Common Stock | $1,000 | $0 | $1,000 | $1,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $1,704,000 | $984,000 | $1,385,000 | $1,747,000 |
| Current Capital Lease Obligation | $706,000 | $401,000 | $362,000 | $326,000 |
| Net PPE | $3,222,000 | $2,217,000 | $2,606,000 | $2,199,000 |
| Accumulated Depreciation | $-448,000 | $-204,000 | $-47,000 | $0 |
| Gross PPE | $3,670,000 | $2,421,000 | $2,653,000 | $2,199,000 |
| Other Properties | $3,578,000 | $2,374,000 | $2,625,000 | $2,199,000 |
| Machinery Furniture Equipment | $92,000 | $47,000 | $28,000 | $0 |
| Dueto Related Parties Current | - | $0 | $141,000 | $0 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-16,656,000 | $-12,085,000 | $-6,896,000 | $-4,066,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-16,394,000 | $-11,901,000 | $-6,401,000 | $-4,066,000 |
| Cash Flow From Continuing Operating Activities | $-16,394,000 | $-11,901,000 | $-6,401,000 | $-4,066,000 |
| Operating Gains Losses | $273,000 | $-5,722,000 | $7,308,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-262,000 | $-184,000 | $-495,000 | - |
| Investing Cash Flow | $-262,000 | $-184,000 | $-495,000 | $0 |
| Cash Flow From Continuing Investing Activities | $-262,000 | $-184,000 | $-495,000 | $0 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $6,590,000 | $7,507,000 | $16,138,000 | $2,150,000 |
| Financing Cash Flow | $7,565,000 | $16,907,000 | $13,793,000 | $5,925,000 |
| Cash Flow From Continuing Financing Activities | $7,565,000 | $16,907,000 | $13,793,000 | $5,925,000 |
| Net Common Stock Issuance | $6,590,000 | $7,507,000 | $0 | - |
| Common Stock Issuance | $6,590,000 | $7,507,000 | $0 | - |
| Net Preferred Stock Issuance | - | $0 | $16,138,000 | $2,150,000 |
| Preferred Stock Issuance | - | $0 | $16,138,000 | $2,150,000 |
| Net Other Financing Charges | - | - | $-2,645,000 | - |
| Other | ||||
| Repayment Of Debt | $-3,400,000 | $0 | $0 | $-525,000 |
| Issuance Of Debt | $4,375,000 | $9,400,000 | $300,000 | $4,300,000 |
| Interest Paid Supplemental Data | $204,000 | $20,000 | $2,000 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $4,894,000 | $13,985,000 | $9,163,000 | $2,266,000 |
| Beginning Cash Position | $13,985,000 | $9,163,000 | $2,266,000 | $407,000 |
| Changes In Cash | $-9,091,000 | $4,822,000 | $6,897,000 | $1,859,000 |
| Net Issuance Payments Of Debt | $975,000 | $9,400,000 | $300,000 | $3,775,000 |
| Net Short Term Debt Issuance | $975,000 | $9,400,000 | $300,000 | $3,775,000 |
| Short Term Debt Payments | $-3,400,000 | $0 | $0 | $-525,000 |
| Short Term Debt Issuance | $4,375,000 | $9,400,000 | $300,000 | $4,300,000 |
| Net PPE Purchase And Sale | $-262,000 | $-184,000 | $-495,000 | $0 |
| Purchase Of PPE | $-262,000 | $-184,000 | $-495,000 | $0 |
| Change In Working Capital | $-3,312,000 | $559,000 | $493,000 | $307,000 |
| Change In Other Current Liabilities | $-550,000 | $-362,000 | $-326,000 | $-220,000 |
| Change In Other Current Assets | $-30,000 | $-2,000 | $14,000 | $-6,000 |
| Change In Payables And Accrued Expense | $-1,502,000 | $1,112,000 | $812,000 | $525,000 |
| Change In Payable | $-1,502,000 | $1,112,000 | $812,000 | $525,000 |
| Change In Account Payable | $-1,502,000 | $1,253,000 | $671,000 | $525,000 |
| Change In Prepaid Assets | $-1,230,000 | $-189,000 | $-7,000 | $8,000 |
| Stock Based Compensation | $2,686,000 | $2,219,000 | $1,765,000 | $265,000 |
| Unrealized Gain Loss On Investment Securities | $1,773,000 | $-232,000 | $0 | - |
| Depreciation Amortization Depletion | $832,000 | $573,000 | $437,000 | $94,000 |
| Depreciation And Amortization | $832,000 | $573,000 | $437,000 | $94,000 |
| Depreciation | $832,000 | $573,000 | $437,000 | $94,000 |
| Gain Loss On Investment Securities | $-352,000 | $-5,722,000 | $7,308,000 | - |
| Net Income From Continuing Operations | $-18,646,000 | $-11,161,000 | $-16,485,000 | $-5,121,000 |
| Other Non Cash Items | - | $1,863,000 | $81,000 | $389,000 |
Fetched: 2026-06-17